-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although some progress has been made in the treatment of diabetes , optimal blood sugar control is usually not achieved.
Diabetes many anti-diabetic drugs can cause hypoglycemia and weight gain, which may affect the implementation and long-term "enhanced" treatment of a number of anti-diabetic drugs can cause hypoglycemia and weight gain, which may affect the implementation and long-term "enhanced" treatment Apply hypoglycemia
Glucagon-like peptide 1 (GLP-1)-based treatments, such as GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransport Protein 2 (SGLT2) can control blood sugar by increasing glucose-dependent insulin secretion, slowing down gastric emptying, reducing postprandial glucagon, and reducing food intake.
The effect of GLP-1 on glucose homeostasis reflects the incretin effect, that is, under the same change in blood glucose level, oral glucose stimulates insulin secretion more than intravenous glucose .
The effect of GLP-1 on glucose homeostasis reflects the incretin effect, that is, under the same level of blood glucose change, oral glucose stimulates insulin secretion more than intravenous glucose , that is, under the same level of blood glucose change, oral glucose has an effect on insulin The stimulating effect of secretion is greater than that of intravenous glucose , that is, under the same change in blood sugar level, the stimulating effect of oral glucose on insulin secretion is greater than that of intravenous glucose .
medsci.
The researchers selected randomized placebo-controlled trials of SGLT2is and GLP-1RAs published from January 1, 2015 to December 8, 2020, for meta-analysis.
The results showed that, in general, among all the types of drugs tested, GLP-1 receptor agonists have a greater advantage in improving the risk of myocardial infarction and stroke in Asians compared with whites.
Among all the types of drugs tested, GLP-1 receptor agonists have a greater advantage in improving the risk of myocardial infarction and stroke in Asians compared to whites.
Specifically, in the 4 SGLT2i trials of type 2 diabetes, the MACE results (95% CI) of 3298 Asians and 20258 whites were 0.
In the 4 SGLT2i trials of type 2 diabetes, the MACE results (95% CI) of 3298 Asians and 20258 whites were 0.
In the heart failure trial, the potential effect of SGLT2 inhibitors on Asian populations is still better than that of whites.
Compared with whites, Asians may gain greater cardiovascular death/ heart failure benefits from SGLT2is, and in patients with type 2 diabetes, MACE benefits from GLP-1RAs.
references:
Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.
https://doi.
Leave a message here
